Skip to main content
Premium Trial:

Request an Annual Quote

Fisher and Nanogen Will Share IP, Technologies to Co-Develop Molecular Dxs

NEW YORK (GenomeWeb News) – Nanogen and Fisher Scientific International today said they will share each other's technology and patent rights in order to develop, manufacture, and market new molecular diagnostic products.
As part of the deal, which complements Fisher's equity investment in Nanogen in March, Fisher “may provide” Nanogen up to $10 million during 2007 and 2008 to research and develop infectious disease and molecular diagnostic tests “that will be mutually agreed upon.”
Additionally, Nanogen and Fisher’s Athena Diagnostics subsidiary plan to manufacture and market products based on Athena's biomarkers for research and for in vitro diagnostic use.
Athena has markers in neurology and endocrinology that it has incorporated into its testing service, several of which could be incorporated into assays for use on Nanogen's NanoChip400 microarray platform, Fisher and Nanogen said.
“Likewise,” Nanogen has access to a “wide range of markers” that could be used to create tests for the Athena Diagnostics testing service.
Additional details were not disclosed.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.